Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Docetaxel as 2nd Line Treatment in Advanced NSCLC
ChiCTR-OPC-17011722Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Feb 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: progression-free survival. Started Feb 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-17011722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011722.